Floatz logo

MIDAZOLAM

Mastectomy

University of Alabama at BirminghamSmall moleculeEarly Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Mastectomy cohort.

Asset / SponsorPhaseRating
Naproxen
Nanjing Medical University
Phase 4BB
DICLOFENAC
Nanjing Medical University
Phase 4BB
Oxycodone
Nanjing Medical University
Phase 4B
Dfn-15
Nanjing Medical University
Phase 4B
FENTANYL
Xiaguang Duan
Early Phase 1CC

View all 17 →

Same molecule, other indications

MIDAZOLAM is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
75 / 100
View asset →
neuralgiaDormant
BBB
Indicative ·
75 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →